Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634
This examiner grants 27% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17270396 | CAS9 VARIANTS HAVING NON-CANONICAL PAM SPECIFICITIES AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | Non-Final OA | DYNO THERAPEUTICS, INC. |
| 17904565 | Adeno-Associated Viral (AAV)-Mediated Sgpl1 Gene Therapy For Treatment Of Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS) | Final Rejection | The Regents of the University of California |
| 17278628 | ANTIGEN DENSITY SENSING MOLECULAR CIRCUITS AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17442471 | ENGINEERED MRNA SEQUENCES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 17820232 | CELL-TO-CELL DELIVERY OF RNA CIRCUITS | Non-Final OA | California Institute of Technology |
| 18551789 | ARSB VECTORS FOR TREATMENT OF MPS VI-ASSOCIATED BLINDNESS AND OTHER OCULAR MANIFESTATIONS | Non-Final OA | North Carolina State University |
| 17275399 | SLOW-CYCLING CELL-RNA BASED NANOPARTICLE VACCINE TO TREAT CANCER | Final Rejection | University of Florida Research Foundation, Inc. |
| 17772017 | Gene Therapy Approaches to Mucolipidosis IV (MLIV) | Final Rejection | The General Hospital Corporation |
| 17609181 | METHOD TO INDUCE HEMATOPOIETIC CHIMERISM | Final Rejection | The General Hospital Corporation |
| 17772266 | GENE THERAPY VECTORS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17435004 | Off-Target Single Nucleotide Variants Caused by Single-Base Editing and High-Specificity Off-Target-Free Single-Base Gene Editing Tool | Non-Final OA | Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences |
| 17836693 | Methods for Generating Cardiac Fibroblasts | Final Rejection | Wisconsin Alumni Research Foundation |
| 17800338 | Viral vector particle based on AA V2 for gene therapy | Non-Final OA | Medizinische Hochschule Hannover |
| 17615453 | COMPOSITIONS AND PROCESS FOR INTEGRATING CELLS INTO EPITHELIUM | Final Rejection | Medizinische Hochschule Hannover |
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | Final Rejection | UNIVERSITÉ DE MONTPELLIER |
| 17514828 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | CREATE Medicines, Inc. |
| 17792076 | CARTILAGE DAMAGE TREATMENT MATERIAL UTILIZING BONE MARROW FLUID | Final Rejection | Mochida Pharmaceutical Co., Ltd. |
| 17111769 | Modified Guide RNAs for Gene Editing | Final Rejection | Intellia Therapeutics, Inc. |
| 17778482 | DIRECTED CHANGES IN ORGANISM POPULATIONS | Non-Final OA | Trustees of Tufts College |
| 17090706 | N-Glycosylation | Final Rejection | Danmarks Tekniske Universitet |
| 17630885 | LENTIVIRAL TRANSDUCTION METHODS | Final Rejection | Adaptimmune Limited |
| 17265484 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18265248 | ONCOLYTIC HERPES SIMPLEX TYPE 1 VIRUSES FOR TREATMENT OF BRAIN TUMORS | Non-Final OA | IMMVIRA CO., LIMITED |
| 18039734 | Vector | Non-Final OA | Fondazione Telethon |
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | Non-Final OA | DEVACELL, INC. |
| 18030407 | LIVE BIOTHERAPEUTICS SECRETING SYNTHETIC BACTERIOPHAGES IN THE TREATMENT OF CANCER | Non-Final OA | TATUM BIOSCIENCE INC. |
| 18014112 | HUMAN LONG-TERM HEMATOPOIETIC STEM CELL MARKER | Non-Final OA | NEXTGEM INC. |
| 17775922 | Production System | Final Rejection | Oxford BioMedica (UK) Limited |
| 17746228 | Recombinant Adeno-Associated Virus Delivery of Alpha-Sarcoglycan Polynucleotides | Final Rejection | NATIONWIDE CHILDREN'S HOSPITAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy